{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:30:34Z","timestamp":1760239834988,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Frank and Betty Vandermeer","award":["K24CA184039"],"award-info":[{"award-number":["K24CA184039"]}]},{"name":"Sonya and Tom Campion"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.hoc.2020.02.008","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T17:19:51Z","timestamp":1586452791000},"page":"727-741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Phosphatidylinositol-3-Kinase Inhibition in Follicular Lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Ryan C.","family":"Lynch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2020.02.008_bib1","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2020.02.008_bib2","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.008_bib3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.02.008_bib4","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2020.02.008_bib5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1080\/13543784.2017.1384815","article-title":"PI3Kdelta-selective and PI3Kalpha\/delta-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma","volume":"26","author":"Lampson","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.hoc.2020.02.008_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.hoc.2020.02.008_bib7","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1084\/jem.20020805","article-title":"A\u00a0crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation","volume":"196","author":"Clayton","year":"2002","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.hoc.2020.02.008_bib8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.008_bib9","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2011-10-386763","article-title":"PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma","volume":"119","author":"Meadows","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.008_bib10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature13444","article-title":"Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer","volume":"510","author":"Ali","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2020.02.008_bib11","doi-asserted-by":"crossref","first-page":"8526","DOI":"10.1200\/jco.2013.31.15_suppl.8526","article-title":"Final results of a phase I study of idelalisib, a selective inhibitor of PI3K\u03b4, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)","volume":"31","author":"Benson","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.008_bib12","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.02.008_bib13","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","article-title":"FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma","volume":"21","author":"Miller","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2020.02.008_bib14","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.02.008_bib15","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.008_bib16","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2020.02.008_bib17","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1182\/blood-2016-12-757740","article-title":"Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy","volume":"129","author":"Gopal","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.008_bib18","unstructured":"Gilead Sciences Inc: Idelalisib prescriber information, Revised 10\/2018, Available at: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/zydelig\/zydelig_pi.pdf. Accessed September 19, 2019,"},{"key":"10.1016\/j.hoc.2020.02.008_bib19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.008_bib20","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.008_bib21","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.008_bib22","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A\u00a0phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia","volume":"126","author":"O'Brien","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.008_bib23","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4049\/jimmunol.1701703","article-title":"The PI3K p110delta isoform inhibitor idelalisib preferentially inhibits human regulatory T\u00a0cell function","volume":"202","author":"Chellappa","year":"2019","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.hoc.2020.02.008_bib24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.008_bib25","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of Duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.008_bib26","first-page":"493","article-title":"Results from the phase 3 DUOTM Trial: a randomized comparison of Duvelisib Vs Ofatumumab in patients with relapsed\/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"130","author":"Flinn","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.008_bib27","unstructured":"Verastem Inc: Duvelisib prescriber information, Revised 9\/2018. Available at: https:\/\/www.verastem.com\/wp-content\/uploads\/2018\/08\/prescribing-information.pdf. Accessed September 20, 2019."},{"key":"10.1016\/j.hoc.2020.02.008_bib28","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann Oncol"},{"issue":"35","key":"10.1016\/j.hoc.2020.02.008_bib29","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.008_bib32","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1182\/blood.V124.21.1984.1984","article-title":"TGR-1202, a novel once daily PI3K\u03b4 inhibitor, demonstrates clinical activity with a favorable safety profile, lacking hepatotoxicity, in patients with chronic lymphocytic leukemia and B-cell lymphoma","volume":"124","author":"Burris","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.008_bib33","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1158\/1538-7445.AM2016-545","article-title":"Abstract 545: differential regulation of human T-cells by TGR-1202, a novel PI3K\u03b4 inhibitor","volume":"76","author":"Maharaj","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2020.02.008_bib34","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","article-title":"Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study","volume":"19","author":"Burris","year":"2018","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2020.02.008_bib36","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood.2019002118","article-title":"Ublituximab and Umbralisib in relapsed\/refractory B-cell non-hodgkin lymphoma and chronic lymphocytic leukemia","volume":"134","author":"Lunning","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.008_bib37","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1200\/JCO.2018.36.15_suppl.7519","article-title":"Initial results of a dose escalation study of a selective and structurally differentiated PI3K\u03b4 inhibitor, ME-401, in relapsed\/refractory (R\/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL)","volume":"36","author":"Soumerai","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.008_bib38","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1200\/JCO.2019.37.15_suppl.7512","article-title":"Results of the PI3K\u03b4 inhibitor ME-401 alone or with rituximab in relapsed\/refractory (R\/R) follicular lymphoma (FL)","volume":"37","author":"Zelenetz","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.008_bib40","doi-asserted-by":"crossref","first-page":"7530","DOI":"10.1200\/JCO.2017.35.15_suppl.7530","article-title":"Ongoing phase 1\/2 study of INCB050465 for relapsed\/refractory (R\/R) B-cell malignancies (CITADEL-101)","volume":"35","author":"Ramchandren","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.008_bib43","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.3324\/haematol.2017.169656","article-title":"Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"102","author":"Younes","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.02.008_bib44","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2018-99-112757","article-title":"Pooled safety analysis and efficacy of Tenalisib (RP6530), a PI3K\u03b4\/\u03b3 inhibitor, in patients with relapsed\/refractory lymphoid malignancies","volume":"132","author":"Iyer","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2020.02.008_bib54","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/ajh.25634","article-title":"Combination trial of Duvelisib (IPI-145) with rituximab or bendamustine\/rituximab in patients with non-hodgkin lymphoma or chronic lymphocytic leukemia","volume":"94","author":"Flinn","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2020.02.008_bib55","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hon.2439_187","article-title":"Safety run-in of copanlisib in combination with rituximab plus bendamustine in patients with relapsed indolent non-hodgkin's lymphoma","volume":"35","author":"Gerecitano","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.hoc.2020.02.008_bib60","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1200\/JCO.2016.34.15_suppl.7512","article-title":"Long-term follow-up of the PI3K\u03b4 inhibitor TGR-1202 to demonstrate a differentiated safety profile and high response rates in CLL and NHL: integrated-analysis of TGR-1202 monotherapy and combined with ublituximab","volume":"34","author":"Burris","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.02.008_bib62","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1182\/blood.V128.22.2979.2979","article-title":"Contempo: preliminary results in first-line treatment of follicular lymphoma with the oral dual PI3K-\u03b4,\u03b3 inhibitor, duvelisib, in combination with Rituximab or Obinutuzumab","volume":"128","author":"Casulo","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.02.008_bib65","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s40265-017-0838-6","article-title":"Copanlisib: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.hoc.2020.02.008_bib66","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s40265-018-1013-4","article-title":"Duvelisib: first global approval","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:14:04Z","timestamp":1760184844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0889858820300332"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.02.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphatidylinositol-3-Kinase Inhibition in Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}